Estimating Vaccine Potency Using Antibody-Based Competition Assays.

Autor:	Doering J; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA., Van Slyke G; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA., Donini O; Soligenix, Inc, Princeton, NJ, USA., Mantis NJ; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA. nicholas.mantis@health.ny.gov.
Jazyk:	angličtina
Zdroj:	Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2022; Vol. 2410, pp. 693-705.
DOI:	10.1007/978-1-0716-1884-4_37
Abstrakt:	The issues of vaccine potency and stability constitute formidable challenges associated with the development and readiness of vaccines for biodefense. In most instances, the vaccines will be stockpiled (at considerable cost) for years and used only in the rare event of a public health emergency. It is therefore imperative that there be means to readily monitor overall stability of the stockpiled vaccines, preferably using reliable in vitro assays, without the need for expensive and labor-intensive animal studies. In this chapter, we describe an in vitro monoclonal antibody-based competition ELISA known as RiCoE for assessing the potency of a ricin toxin subunit vaccine. RiCoE can be applied to drug substance and drug products adsorbed to aluminum salts adjuvant. While RiCoE is specific for ricin toxin, the general methodologies and protocols described herein are amenable to virtually any subunit or even virus-like particle-based vaccine. Ultimately, RiCoE-like assays may replace or at least reduce the need for animal studies in vaccine potency determinations. (© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu